S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
New CBOE “special perk” helps traders target income every weekend (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
New CBOE “special perk” helps traders target income every weekend (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
New CBOE “special perk” helps traders target income every weekend (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
New CBOE “special perk” helps traders target income every weekend (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases

MiMedx Group Stock Price, News & Analysis (NASDAQ:MDXG)

$7.99
+0.22 (+2.83%)
(As of 12/1/2023 ET)
Compare
Today's Range
$7.61
$7.99
50-Day Range
$5.70
$7.99
52-Week Range
$2.43
$8.60
Volume
626,117 shs
Average Volume
651,481 shs
Market Capitalization
$929.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.67

MiMedx Group MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
46.0% Upside
$11.67 Price Target
Short Interest
Healthy
3.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of MiMedx Group in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$35,800 Bought Last Quarter
Proj. Earnings Growth
277.78%
From $0.09 to $0.34 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.64 out of 5 stars

Medical Sector

101st out of 954 stocks

Surgical & Medical Instruments Industry

17th out of 95 stocks


MDXG stock logo

About MiMedx Group Stock (NASDAQ:MDXG)

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

MDXG Stock Price History

MDXG Stock News Headlines

MiMedx Group Inc MDXG
MIMEDX to Participate in Upcoming Investor Conferences
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
MIMEDX to Highlight Published Data at SAWC Fall
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Q3 2023 MiMedx Group Inc Earnings Call
MiMedx Group Q3 Earnings Preview
Unraveling MiMedx's Surgical Precision In Growth
MIMEDX Announces Launch of EPIEFFECT™
MDXG: Beat and a Raise
Q2 2023 MiMedx Group Inc Earnings Call
H.C. Wainwright Sticks to Their Buy Rating for MiMedx Group (MDXG)
See More Headlines
Receive MDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/30/2023
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDXG
Employees
867
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.67
High Stock Price Target
$12.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+46.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-30,200,000.00
Pretax Margin
1.60%

Debt

Sales & Book Value

Annual Sales
$267.84 million
Book Value
$0.01 per share

Miscellaneous

Free Float
93,218,000
Market Cap
$929.88 million
Optionable
Optionable
Beta
1.63
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. William F. Hulse IV (Age 49)
    General Counsel & Chief Administrative Officer
    Comp: $677.36k
  • Dr. Robert Benjamin Stein M.D. (Age 72)
    Ph.D., President of Regenerative Medicine & Biologics Innovation
    Comp: $639.28k
  • Mr. Joseph H. Capper (Age 59)
    CEO & Director
  • Mr. Douglas C. Rice CPA (Age 57)
    Chief Financial Officer
  • Mr. Scott M. Turner (Age 57)
    Senior Vice President of Operations & Procurement
    Comp: $493.98k
  • Mr. Matthew M. Notarianni
    Head of Investor Relations
  • Mr. Mark P. Graves (Age 57)
    Senior VP & Chief Compliance Officer
  • Hilary Dixon
    Vice President of Investor Relations & Corporate Strategic Communications
  • Ms. Kate Surdez
    Chief Human Resources Officer
  • Dr. David H. Mason Jr. (Age 76)
    Chief Medical Officer














MDXG Stock Analysis - Frequently Asked Questions

Should I buy or sell MiMedx Group stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDXG shares.
View MDXG analyst ratings
or view top-rated stocks.

What is MiMedx Group's stock price target for 2024?

3 brokerages have issued 1 year target prices for MiMedx Group's stock. Their MDXG share price targets range from $11.00 to $12.00. On average, they expect the company's share price to reach $11.67 in the next twelve months. This suggests a possible upside of 46.0% from the stock's current price.
View analysts price targets for MDXG
or view top-rated stocks among Wall Street analysts.

How have MDXG shares performed in 2023?

MiMedx Group's stock was trading at $2.78 at the beginning of the year. Since then, MDXG shares have increased by 187.4% and is now trading at $7.99.
View the best growth stocks for 2023 here
.

When is MiMedx Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our MDXG earnings forecast
.

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc. (NASDAQ:MDXG) posted its quarterly earnings results on Monday, October, 30th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.01. The company earned $81.71 million during the quarter, compared to analyst estimates of $76.69 million.

What ETF holds MiMedx Group's stock ?

Invesco Nasdaq Future Gen 200 ETF holds 5,917 shares of MDXG stock, representing 0.64% of its portfolio.

Who are MiMedx Group's major shareholders?

MiMedx Group's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cannell Capital LLC (1.95%), Richmond Brothers Inc. (1.27%), Charles Schwab Investment Management Inc. (0.92%), Northern Trust Corp (0.92%), Federated Hermes Inc. (0.72%) and Royal Bank of Canada (0.71%). Insiders that own company stock include Mark Graves, Peter M Carlson, Rice Doug, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan.
View institutional ownership trends
.

How do I buy shares of MiMedx Group?

Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MDXG) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -